⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953092 | 0.76 | — | — | |
| SCHEMBL9638546 | 0.74 | — | — | |
| SCHEMBL22035326 | 0.74 | PTGER4 (0.36) | — | |
| SCHEMBL15507325 | 0.74 | KDM4E (0.42) | — | |
| SCHEMBL16968066 | 0.74 | KDM4E (0.42) | — | |
| SCHEMBL23235966 | 0.69 | MEN1 (0.36) | — | |
| SCHEMBL17260754 | 0.69 | KDM4E (0.31) | — | |
| SCHEMBL15707248 | 0.69 | — | — | |
| SCHEMBL8538434 | 0.68 | LMNA (0.44) | — | |
| SCHEMBL27396039 | 0.68 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-115279761-B | Crystal of imidazopyridone compound or salt thereof | 橘生药品工业株式会社 | 2025-03-14 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240425504-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (assignee) (JP) | 2024-12-26 | — | — | US | disclosed |
| EP-3808747-B1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL (JP) | 2024-12-18 | — | — | EP | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-12077531-B2 | Imidazopyridinone compound | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-09-03 | — | — | US | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010148351-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010007756-A1 | PYRIDINE DERIVATIVE HAVING TTK INHIBITION ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
| EP-2021381-A2 | HAFNIUM COMPLEXES OF HETEROCYCLIC ORGANIC LIGANDS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2018390-A2 | ORTHO-METALLATED HAFNIUM COMPLEXES OF IMIDAZOLE LIGANDS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018391-A2 | IMPROVED HAFNIUM COMPLEXES OF HETEROCYCLIC ORGANIC LIGANDS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007130306-A2 | ORTHO-METALLATED HAFNIUM COMPLEXES OF IMIDAZOLE LIGANDS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130242-A2 | HAFNIUM COMPLEXES OF HETEROCYCLIC ORGANIC LIGANDS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130307-A2 | IMPROVED HAFNIUM COMPLEXES OF HETEROCYCLIC ORGANIC LIGANDS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-11-15 | — | — | WO | disclosed |